Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | PDE5A | O76074 | 13/20 | 0.56 |
| ▸ | GUCY1A1 | Q02108 | 5/20 | 0.54 |
| ▸ | GUCY1B1 | Q02153 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154434 | 0.89 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174847 | 0.88 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL175007 | 0.88 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL1930775 | 0.87 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL18496411 | 0.87 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL4939648 | 0.87 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16106158 | 0.87 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL175433 | 0.86 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL27557146 | 0.86 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16106157 | 0.86 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105358-B | Non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscle or neuromuscular diseases | 拜耳公司 | 2023-10-13 | — | — | CN | claimed |
| CN-112105358-A | Non-steroidal mineralocorticoid receptor antagonists for use alone or in combination in the treatment of muscular or neuromuscular diseases | 拜耳公司 | 2020-12-18 | — | — | CN | claimed |
| WO-2018096550-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL(METHYL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-31 | — | — | WO | claimed |
| CN-112105358-B | Non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscle or neuromuscular diseases | 拜耳公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113750102-A | Stimulators and/or activators of soluble guanylate cyclase and uses thereof | 拜耳制药股份公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-113712969-A | Stimulators and/or activators of soluble guanylate cyclase and uses thereof | 拜耳制药股份公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-108430510-B | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with inhibitors of neutral endopeptidase (NEP inhibitors) and/or angiotensin AII antagonists and uses thereof | 拜耳制药股份公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112105358-A | Non-steroidal mineralocorticoid receptor antagonists for use alone or in combination in the treatment of muscular or neuromuscular diseases | 拜耳公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2018096550-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL(METHYL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-31 | — | — | WO | disclosed |